MedTrace Logo

Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude

NCT03539367 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-11-02

No results posted yet for this study

Summary

Randomized, placebo controlled trial evaluating the effect of acetazolamide on lung water content by ultrasound in lowlanders older than 40 years travelling from 760 m to 3'100 m.

Conditions

  • Altitude Hypoxia

Interventions

DRUG

ACETAZOLAMIDE oral capsule

Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m

DRUG

Placebo oral capsule

Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m

Sponsors & Collaborators

  • National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov

    collaborator OTHER_GOV

  • University of Zurich

    lead OTHER

Principal Investigators

  • Konrad E Bloch, MD · University Hospital, Zürich

  • Talant M Sooronbaev, MD · National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan

  • Michael Furian, MSc · University Hospital, Zürich

  • Silvia Ulrich, MD · University Hospital, Zürich

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Kyrgyzstan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03539367 on ClinicalTrials.gov